Astellas builds case for menopause drug fezolinetant

New data for Astellas Pharma’s non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, consolidating the evidence of the drug as it starts

FDA undoes Astellas’ bid for fast review of menopause drug

Pharma company had used a priority review voucher to speed up review of fezolinetant.

Bayer extends elinzanetant trials to include breast cancer

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast ca

Astellas files menopause drug fezolinetant in US, setting up...

Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-

Astellas' eyes filings for menopause drug fezolinetant after...

Astellas looks to be in pole position to bring a new non-hormonal therapy for symptoms of menopause to market, after its candidate fezolinetant cleared a phase 3 safety study.

Astellas pushes non-hormonal menopause drug into phase 3